Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
EloraTZP
An experimental combination of the amylin receptor agonist eloralintide with tirzepatide, studied as a combination rather than a single new molecule.
Eloralintide
An investigational selective amylin-pathway agonist now in a broad Phase 3 programme.
How far human research has progressed
EloraTZP
Phase 2b controlled human efficacy data presented at EASD 2026; Phase 3 planned for Q4 2026Eloralintide
Phase 3 programme actively enrolling; published human data limitedClaim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
EloraTZP
Not separately assessed; see the full profile.Eloralintide
Not separately assessed; see the full profile.Human research context
EloraTZP
Phase 2b controlled human efficacy data presented at EASD 2026; Phase 3 planned for Q4 2026Eloralintide
Phase 3 programme actively enrolling; published human data limitedHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
EloraTZP
Eloralintide
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
EloraTZP
Eloralintide
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
EloraTZP
Eloralintide
Regulatory status (legal position, not proof it works)
EloraTZP
Check jurisdiction-specific details in the profile.
Not approved as a combination anywhere. Tirzepatide is separately approved in its own right; that approval does not extend to this combination, which has to be established on its own evidence.
Eloralintide
Check jurisdiction-specific details in the profile.
Not approved anywhere. The Phase 3 ENLIGHTEN programme is enrolling across obesity, type 2 diabetes, obstructive sleep apnoea, knee osteoarthritis and people already on incretin therapy.
Common claims
EloraTZP
- · More weight loss than tirzepatide alone
- · The new standard of care
Eloralintide
- · Weight loss without incretin-style gastrointestinal burden
- · Useful added on top of existing incretin therapy
How settled our evidence rating is
EloraTZP
Eloralintide
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
EloraTZP
Not established for the combination. Class-level incretin considerations from the tirzepatide component apply.Eloralintide
No established human cancer signal for this compound.What this adds up to, in plain English
EloraTZP
Preliminary human observations exist, but they may not establish a treatment-attributable benefit.Eloralintide
Preliminary human observations exist, but they may not establish a treatment-attributable benefit.A comparison is not a recommendation